Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
about
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advancesIncreased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritisMHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo.Genetic Variation in Toll-Interacting Protein Is Associated With Leprosy Susceptibility and Cutaneous Expression of Interleukin 1 Receptor Antagonist.Targeting Imbalance between IL-1β and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse CorneasA Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Distinct role of IL-1β in instigating disease in Sharpincpdm mice.IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.Phytomedicine in Joint Disorders.New discovery rarely runs smooth: an update on progranulin/TNFR interactionsIL-24 Promotes Pseudomonas aeruginosa Keratitis in C57BL/6 Mouse Corneas.Co-morbidity of PTSD and immune system dysfunction: opportunities for treatment.Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarminsUnderstanding Human Autoimmunity and Autoinflammation Through Transcriptomics.The inflammasome as a target for pain therapy.Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.A Brief History of IL-1 and IL-1 Ra in Rheumatology.Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.Microbiota and caspase-1/caspase-8 regulate IL-1β-mediated bone disease.Peptide-mediated delivery of donor mitochondria improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation.Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure.Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance.Aspergillosis in Chronic Granulomatous Disease.IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.Ebosin: a potential therapeutic agent for rheumatoid arthritis and autoinflammatory syndromes.Tocilizumab in patients with multisystem Erdheim-Chester disease.Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.Myocarditis: An Interleukin-1-Mediated Disease?Anakinra Therapy for Non-cancer Inflammatory Diseases
P2860
Q26744624-AD1E760B-754C-4EBD-8E24-FA5D1AC2F41DQ28070056-211466B3-CFAA-4E71-8B74-6BDD9255F7B4Q33750548-0D9EBAF2-35FE-4D0C-A766-B3AA9299B7A9Q34509937-1F64F7F7-9B8F-4278-9871-E53DA04F07A0Q36654569-EEAB3D3A-32B1-4F30-810C-3E8BC863E11EQ36990254-EC757574-5C38-42DB-87F8-2073F325DC36Q37361075-E2FFF318-D6D0-4ABB-AA54-64FCF9225B3AQ37444344-3727E441-095B-46F2-828A-30D72B9D3782Q37614491-7532C70C-2D26-485D-90E3-3D8E9AB79121Q37628462-E08E5ED5-8AA7-4351-AE82-F4D56CE4E5FDQ38593074-64BF2272-B0C1-4E16-A9A7-B4C0A86F3F10Q38711141-C3BEF578-8136-4B95-9C55-3A5756A024FDQ38914928-A7D118E9-9494-44AD-98C8-5D5F5464CBD4Q38927961-BCA4C4B1-2CC1-4FCA-A496-4B60DC0855C0Q38939435-ECC6F27E-07B7-46D8-A695-D36C027DF4F0Q38988559-B5BE3021-1E86-4946-AC14-2EB2D31272D8Q39036848-2AE88EA4-7CE1-4FA3-B868-A98C1268BC50Q39084627-5A6AE91C-A0C8-43B0-969E-B6473DAF3C3AQ39355336-63AC964B-D5A7-43DC-8ACF-1FC035B56E07Q40561232-7FB24E55-3FF6-40AB-941E-70B97F90ED86Q40686369-E7E5C8C9-947C-4606-9A9C-9377EDF2FB53Q41631329-5C301A33-0CE8-445F-869F-10D508A4356BQ41785739-B02BC2AD-6723-47A0-9C9A-BEF1DDE946BEQ42318107-57CCEE4A-7F83-4A60-A196-B791A9EA108DQ47645142-74902900-C737-4E05-93CD-B5F20FBC8ABFQ49461527-8072F69F-9FB4-4AFD-A6EC-F201DAF3FE5EQ50049021-36A0B64A-8D53-436D-81CE-F8B2B28E67ADQ52763513-93415B01-5794-4471-AA39-07A439E8955FQ55025616-E0F3596A-0F8B-4BF8-8E4D-8640050D86D8Q55360198-B1B69B76-8EA4-431F-B0E3-3670BB5B6EB3Q55397626-E36F14CD-6E80-4CE8-B1E4-B4BFDC381E5EQ59136398-2B946C77-94EE-4C75-B2EB-2B9BD0658C96
P2860
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Treating rheumatological disea ...... terleukin-1 blocking therapies
@ast
Treating rheumatological disea ...... terleukin-1 blocking therapies
@en
Treating rheumatological disea ...... terleukin-1 blocking therapies
@nl
type
label
Treating rheumatological disea ...... terleukin-1 blocking therapies
@ast
Treating rheumatological disea ...... terleukin-1 blocking therapies
@en
Treating rheumatological disea ...... terleukin-1 blocking therapies
@nl
prefLabel
Treating rheumatological disea ...... terleukin-1 blocking therapies
@ast
Treating rheumatological disea ...... terleukin-1 blocking therapies
@en
Treating rheumatological disea ...... terleukin-1 blocking therapies
@nl
P2860
P3181
P356
P1433
P1476
Treating rheumatological disea ...... terleukin-1 blocking therapies
@en
P2093
Giulio Cavalli
P2860
P304
P3181
P356
10.1093/RHEUMATOLOGY/KEV269
P407
P577
2015-12-01T00:00:00Z